Evidence map›Paper›PMID 40029791›Full record

ArticleCancer science2025

Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma.

Yusuke Ito, Toshihiro Suzuki, Manami Shimomura, Kazumasa Takenouchi, Kazunobu Ohnuki, Kayoko Shoda, Yuka Kenmochi, Shigeki Yagyu, Kazuto Matsuura, Ryuichi Hayashi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yusuke ItoDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0009-0003-9709-1315
Toshihiro SuzukiDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Manami ShimomuraDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Kazumasa TakenouchiDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Kazunobu OhnukiDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Kayoko ShodaDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Yuka KenmochiDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Shigeki YagyuInnovative Research and Liaison Organization, Shinshu University, Matsumoto, Japan.ORCID https://orcid.org/0000-0003-4256-9783
Kazuto MatsuuraDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Ryuichi HayashiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Tetsuya NakatsuraDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0000-0003-3918-2385

Funding

Japan Agency for Medical Research and Development JP23ck0106659Japan Agency for Medical Research and Development JP24ck0106921
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) represents the most common type of oral cancer, and its prognosis remains poor. In this study, we found that almost OSCC cases showed high Ephrin type-B receptor 4 (EPHB4) expression that was mainly localized on the membrane of tumor cells. Therefore, EPHB4 represents a potential target of chimeric antigen receptor (CAR) T cell therapy for OSCC treatment. Because the oral cavity can be directly accessed, local administration of CAR-T cells is feasible for treating OSCC. In this study, we investigated the efficacy of intratumoral injection of EPHB4-specific CAR-T cells in OSCC using xenograft models. To evaluate the anti-tumor effect, the SAS OSCC cell line or an OSCC patient-derived xenograft (PDX) tumor was subcutaneously implanted into NOD SCID gamma mice, and EPHB4-CAR-T cells were intratumorally injected twice. As expected, administration of CAR-T cells suppressed tumor growth of both SAS cells and PDX tumor. EPHB4 expression in tumor tissues was attenuated by CAR-T cell treatment, which was accompanied by a reduction in tumor area and accumulation of CAR-T cells. Our findings suggest that intratumoral injection of EPHB4-CAR-T cells represents a potential therapeutic strategy for OSCC.

Indexed as

Carcinoma, Squamous CellImmunotherapy, AdoptiveMouth NeoplasmsReceptor, EphB4Receptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorFeasibility StudiesFemaleHumansInjections, IntralesionalMaleMiceMice, Inbred NODMice, SCIDEPHB4 protein, humanReceptor, EphB4Receptors, Chimeric Antigencancer immunotherapychimeric antigen receptor T cell therapyephrin type‐B receptor 4oral cancerpatient‐derived xenograft

Identifiers

PMID40029791
PMCPMC12044661

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.